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ABSTRACT
A MOLECULAR BASIS FOR ERYTHROMYCIN 
SENSITIVITY AND RESISTANCE 
IN ESCHERICHIA £QLX 
by
Harold Chittum
The effect of erythromycin on the 50S riboscanal subunit 
during cell growth has been extensively investigated.
Sucrose density gradient analysis of ribosomes formed in the 
presence and absence of the drug revealed a 50S specific 
assembly defect is partially responsible for erythromycin's 
inhibitory effects on wild type cells. Examination of two 
erythromycin-resistant mutants of E. coli {N281 and N282) 
revealed that mutant N281 (L22 mutant) but not N282 {L4 
mutant) was assembly defective in the presence of the drug, 
although only at much higher drug concentrations (300 ug/ml 
vs. 75 ug/ml for wild type cells).
The altered genes from each mutant have been isolated 
and sequenced. The L22 mutant was found to contain a 9 bp 
deletion which eliminated codons 82-84, and the sequence Met- 
Lys-Arg from the protein. The L4 mutant had an A to G 
transition mutation in codon 63 resulting in a Lys to Glu 
change in the protein. Complementation of each mutant by 
their respective wild type genes resulted in an increased 
sensitivity to the drug in the partial diploid strains.
Two other macrolide antibiotics (oleandomycin and 
spiranycin) were also examined but revealed no apparent 
assembly effect on wild type cells. The MLS antibiotics also 
appeared to be unable to effect assembly. However, the 
erythromycin derivative azithronycin showed a similar effect 
on assembly to that of the parent compound although 
clarithromycin (another erythromycin derivative) did not. 
These resultB suggest erythromycin and azithronycin effect 
assembly through rlbosomal protein L4 and to a lesser extent 
through protein L22.
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Chapter 1 
Introduction
The study of antimicrobial agents has long been of 
interest to researchers due to the medically relevant 
knowledge which can result from their examination. Equally 
as important is the role these drugs play as molecular tools 
for probing the structural and functional domains of their 
cellular targets. Examples include the use of rifaitpicin in 
the study of RNA polymerase {Junjin et al., 1988), the 
isoflavones, flavones and coumarins in the examination of 
topoisomerase II (DNA gyrase) (Robinson et al., 1993) and 
vancomycin as a means of studying the cell wall synthesis 
machinery (Nagarajan, 1991). It seems that virtually every 
major conponent of the bacterial cell is a target for one 
antibiotic or another, making the use of antibiotics a 
powerful means of probing many cellular processes. The 
ribosome 1b no exception as it is the target of many 
antibiotics: the macrolides, lincosamides, streptogrammins, 
puromycin and chloramphenicol to name a few (Vasguez, 1979). 
For this reason antibiotics which target the ribosome can be 
extremely useful in unraveling the details of ribosome 
structure and function relationships. A case in point is the 
construction of a model for the binding sites of puronycin 
and chloramphenicol which helped to define the location of 
the peptidyltransferase center of the large subunit (Moazed 
and Noller, 1987). The macrolides may be equally useful in 
this regard pending a more through understanding of their
1
2mode(s) of action.
Recently, the macrolide antibiotics have gained new 
attention due to their therapeutic importance in combating 
increasingly prevalent pathogens such as Legionella spp., 
Campylobacter leiuni. and Chlamydia trachomatis (Kirst and 
sides, 1989}. The macrolides are an old and well established 
group of drugs which still play a critical role in fighting 
infectious diseases. The fact that they account for 10-15% 
of the worldwide oral antibiotic market makes this point 
clear (Kirst, 1991). In 1950 Brockmann and Henkel isolated 
the first macrolide, pikromycin. The name was chosen due to 
the bitter taste associated with the drug. The chemical 
structures of pikromycin and other related antibiotics were 
later shown to possess a common feature, a macrolactone ring. 
Hence, the term "macrolide" was coined to describe this new 
class of antibiotics. The macrolides are usually grouped 
according to the size of the aglycone compound as 12, 14, or 
16-membered ring macrolides. Most macrolides also contain 
amino or neutral sugar moieties. So far, five amino sugars 
and 11 neutral sugars have been associated with the the 
structures of these drugs. To date only three drugs have 
been found which belong to the 12-menibered ring group of 
macrolides. However, 23 compounds have been isolated which 
belong to the 14-membered ring group and as of 1982, 71 
compounds had been identified in the 16-membered ring 
macrolide group. Erythromycin shows the greatest 
antibacterial activity on cultured bacteria of the macrolide 
antibiotics which are utilized clinically (Gmnra, 1984}. in
3fact, the erythromycins are probably the most well 
investigated members of the 14-membered ring group (Hardy et 
al., 1968).
As it occurs naturally, erythronycin is produced as a 
mixture of three isomers: erythromycins A, B, and C (Omura, 
1984) (Figure 1). The process employs a series of fatty acid 
synthase-like enzyme modules to synthesize the antibiotic 
(Donadio et al., 1991). The predominant component of the 
resulting mixture, erythromycin A (Omura, 1984), has been 
used clinically and possesses broad spectrum activity against 
both Gram positive and some Gram negative bacterial cells 
(Gale et al., 1981; Nakayama, 1984). However, one 
disadvantage of the use of erythromycin is it's low stability 
in an acid environment such as that of the stomach. Under 
conditions of low pH the drug degrades to an inactive 
hemiketal derivative. Therefore, chemical modification of 
erythromycin A began with the goal of resolving this problem 
as well as Improving the water solubility and taste of the 
drug (Omura, 1984). The result was a considerable wealth of 
information concerning the structure-activity relationships 
associated with the drug.
Conformational studies using NMR, CD, and X-ray 
crystallography data, demonstrated that the orientation of 
the hydrophilic groups (the ketone carbonyl, lactone 
carbonyl, and hydroxyl groups at positions C-6 and C-ll) and 
the hydrophobic groups (the methyl groups at the C-4, c-8, 
and C-12 positions and the ethyl group at the c-13 position) 
on the macrolactone ring and the desosamine sugar moiety play
Figure 1. Chemical Structure of Erythromycin. The three 
molecular forms of erythromycin which occur naturally are 
indicated below.
AGLTCOHZ
HEU1SAL SUGAB
Erythromycin A OH CH3
Erythromycin B H CH3
Erythromycin C OH H
5a key role in the biological activity of the drug (Omura,
1984). Mao and Putterman have proposed that the 2' -hydroxyl 
and 3' -dimethylamino groups (on desosamine) form hydrogen 
bonds with the 23S rRNA in the ribosome. The 11,12-hydroxyl,
9-carbonyl, and 3"-methoxyl, and most likely the 6-hydroxyl 
groups of erythromycin A also form additional hydrogen bonds 
(Mao and Putterman, 1969).
Although there have been extensive investigations of the 
mechanism by which erythromycin and other macrolides inhibit 
protein synthesis over the last quarter of a century, 
progress in elucidating the exact process has been slow and 
indecisive. The inhibitory effects of erythromycin and other 
related compounds have probably been most thoroughly 
investigated in Escherichia coli (Corcoran, 1984; Vazquez, 
1979). In this organism, erythromycin interacts with 
components of the 50S subunit associated with the 
peptidyltransferase activity (Vogel et al., 1971).
Association of subunits in the presence of the antibiotic 
appears to proceed normally, producing ribosomes which are 
capable of peptide bond formation (catalyzed by 
peptidyltransferase). Polyribosomes and elongating ribosomes 
also seem to function normally in the presence of the drug 
(Andersson and Kurland, 1987; Tai and Davis, 1979), although 
their distribution on mRNA is apparently influenced by the 
drug as observed by their altered mobilities in agarose- 
polyacrylamide conposite gels (Dahlberg et al., 1973). These 
observations have led to the suggestion that erythromycin 
inhibits a step in translation between initiation and
elongation (Andersson and Kurland, 1987; Tai and Davis, 1979; 
Vester and Garrett, 1987), or effects the P site*dependent 
binding of peptidyl tRNA (Chinali et al., 1988). In cell* 
free translation systems where polypeptides are synthesized 
in response to synthetic polynucleotide mRNAs, there have 
been many reports of differential actions, depending on the 
polynucleotide errployed in the assay. For example, in the 
translation of polyadenylic acid (coding for polylysine) 
erythromycin stimulated the production of di, tri, and 
tetrapeptides, but inhibited formation of oligo or 
polypeptides (Omura, 1984; Tanaka and Teroka, 1966). in a 
polyuridylic acid directed system (coding for 
polyphenylalanine), erythromycin failed to inhibit 
polyphenylalanine formation unless the free 50S subunits were 
first preincubated with the drug (Oleinick and Corcoran,
1969). One hypothesis proposes that erythromycin may bind in 
the ribosomal "tunnel" (located between the two subunits) 
consequently irrtpeding the passage of nascent peptides as 
translation proceeds (Contreras and Vazquez, 1977). 
Unfortunately, a consensus as to the exact mechanism by which 
macrolides inhibit protein synthesis has not been reached 
(Cundliffe, 1980, 1990).
It has been noted that certain differences exist between 
the inhibitory effects produced by various groups of 
macrolides. Therefore, some researchers have suggested that 
the macrolides should be grouped into two categories 
according to their effects on protein synthesis (Arevalo et 
al., 1988; Seigrist et al., 1985; Tejedor and Ballesta,
1985a, 1985b, 1986). The erythromycin group is characterized 
by the presence of monosaccharides on the aglycone ring, 
while the spiramycins are characterized by the presence of 
disaccharides on the aglycone ring, as mentioned previously, 
the erythromycins inhibit chain elongation, but only after 
the formation of several peptide bondB has been completed.
The spiramycins, on the other hand, are thought to be more 
typical peptidyltransferase inhibitors. For example, 
spiramycin is an excellent inhibitor of both the puroniycin 
reaction and the so called * fragment reaction" while 
erythromycin is a poor inhibitor of either unless specific 
aminoacyl-tRNAs are used as a substrate (Arevalo et al.,
1989). The identification of erythromycin-resistant mutants 
which are sensitive to spiraitrycin provides sane evidence that 
the binding sites of the two macrolides may not be identical 
either. Further evidence for this difference lies in the 
fact that the binding site for erythromycin on the 5OS 
subunit is thought to be close to, but not at, the 
peptidyltransferase center (Cooperman et al., 1990). 
Fluorescence energy transfer experiments have suggested a 
distance of 2.3 nm (Wells and Cantor, 1980).
Studies involving ribosomes from Staphylococcus aureuB 
(Mao and Putterman, 1969), Bacillus subtilis (Oleinick and 
Corcoran, 1969) and E. coli (PeBtka, 1974; Teraoka, 1970) 
have allowed the binding parameters of erythromycin to be 
defined and have suggested features of the compound important 
for binding interactions (Mao and Putterman, 1969; PeBtka, 
1974). Erythromycin was shown to bind tightly and
stoichiometrically in a X:l ratio to the 50S ribosomal 
subunit from all three organisms (Oleinick and Corcoran,
1969; Mao and Putterman, 1969; Pestka, 1974). These studies 
also revealed that erythromycin is a competitive inhibitor 
for the binding of virginiamycin S (deflethune and Nierhaus, 
1978) and prevents the binding of chloramphenicol, lincomycin 
and Bpiramycin to the 50S ribosomal subunit (Vazquez, 1979). 
These compounds all inhibit peptide bond formation 
reinforcing the idea that erythromycin does interact with 
ribosomal components at or near the peptidyltransferase 
center. Protein L22 of the large subunit has been shown to 
interact directly with virginiamycin S (DiGiambattista et 
al., 1990). Other work has shown that two different 
photoreactive derivatives of erythromycin specifically bound 
to protein L22 and more weakly to proteins L2, L4 and L15 
(Arevalo et al., 1988). A combination of polyacrylamide gel 
electrophoresis and reverse-phase high-performance liquid 
chromatography (HPLC) approaches were used to identify the 
labeled proteins. In both cases hZZ labeling was inhibited by 
the presence of the unlabeled drug indicating that the 
labeled drugs bound the same region of the ribosome.
Other studleB have focused on the spiramycin-type 
macrolides (Tejedor and Ballesta, 1985a, 1985b, 1986). 
Reduction of the aldehyde group present on each drug allowed 
the production of 3H-labeled dihydro derivatives of carbomycin 
A, niddamycin, and tylosin. All three of these derivatives 
are capable of light-independent incorporation into ribosomal 
proteins, with the first two showing photo-induced
incorporation as well. All five labeling reactions 
consistently showed protein L27 as the major labeled protein. 
Site specificity was demonstrated by the ability of the 
unlabeled macrolides to inhibit covalent binding. Some have 
proposed the idea that these differences can be attributed to 
the different glycosidic substituents present on each drug 
group (Arevalo et al., 1969).
Reconstitution experiments have been useful in 
identifying key components of the erythromycin binding site. 
One study identified proteins L15 and L16 as critical for 
erythromycin binding to the 50S subunit and demonstrated weak 
binding of the antibiotic to isolated protein L15 (Teraoka 
and Nierhaus, 1976}. Each of these proteins has been shown 
to be essential for reconstitution of the peptidyltransferase 
activity of the SOS subunit (Hampl et al., 1961}. in fact, 
recent studies have identified the location of these proteins 
at a common site on the 50S subunit structure (Cooperman et 
al., 1990; Nag et al., 1991).
Genetic studies are another important way in which 
interactions between erythromycin and the ribosome have been 
examined. Resistance to erythromycin can be achieved in 
several wayB. One of the moBt extensively examined has been 
resistance produced by sequence changes in the 23S ribosomal 
RNA. Although resistance to macrolides can occur as a result 
of mutational changes in ribosomal components, the most 
common type of resistance is defined as MLS (Macrolide, 
Lincosamide and streptogramin) resistance (Goldman and Kadam, 
1989). The resistance mechanism involves the dimethylation
io
of a single adenine residue at position 2058 of the 23S rRNA 
by a plasmid-encoded methyItransferase. This mechanism has 
been shown to confer drug resistance in several different 
Gram positive organisms (Skinner et al., 1983). Hie 
methylation results in the production of 50S ribosomal 
subunits which are unable to bind the MLS antibiotics 
(Goldman and Kadam, 1989}. Nucleotide alterations at this 
same site (2058) and in adjacent residues have been shown to 
lead to drug resistance as well (Douthwaite, 1992; Ettayebi 
et al., 1985; Sigmund and Morgan, 1982; Vannuffel et al.,
1992; Vester and Garrett, 1987) or hypersensitivity 
(Douthwaite, 1992} (Figure 2). Sequence analysis and 
protection studies have indicated that changes in either 
domain II or V of the secondary structure of 23S rRNA can 
give rise to erythromycin resistance (Douthwaite et al.,
1985; Moazed and Noller, 1987). In the case of domain V, the 
changes come in the form of point mutations as Figure 2 
indicates. The only domain II change found to produce 
resistance to erythromycin was the deletion of nucleotides 
1219 to 1230. This has been interpreted as evidence of a 
functional tertiary interaction between these two domains of 
the 23S rRNA (Douthwaite et al., 1985). The GTPase- 
associated center of the 23S rRNA which is also located in 
domain II has previously been implicated in antibiotic 
binding. The two drugs involved, thiostrepton and 
micrococcin, both block processes associated with the 
ribosomal A-site (Egebjerg et al., 1989). This would seem 
to lend further credence to the idea of domain II's
Figure 2. Nucleotide Alterations in 23S rRNA Leading to 
Erythromycin Resistance in Escherichia coli and Other 
Organisms. Abbreviations: Ans, anisomycin; Cam, 
chloramphenicol; Cld, clindamycin; Ery, erythromycin; Lnc, 
lincarnycin; Spr, spiramycin; r, resistant; hs, 
hypersensitive; Cc, Chlamydomonas chloroplasts; E.c, £. coli; 
H, Halohacterla: Hu, human mitochondria; M, mouse 
mitochondria; T, Tetrahvmena cytoplasmic ribosomes; tc, 
tobacco chloroplasts; Y, yeast mitochondria.
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interaction with the peptidyltransferase loop of domain V 
(Douthwaite 1992}.
Another way in which resistance to erythromycin can he 
produced is through alterations in a number o£ ribosomal 
proteins. Several different ribosomal protein mutants of 
Escherichia ££2li resistant to high levels of erythromycin 
have been isolated and characterized (Apirion, 1967; Otaka et 
al., 1970; Pardo and Rosset, 1974; Pardo and Rosset, 1977; 
Takata et al., 1970; Wittmann et al., 1973). Mutants altered 
in proteins L4 and L22 have been the most extensively 
investigated (Pardo and Rosset, 1977a; Pardo and Rosset,
1977b; Wittmann et al., 1973). Ribosomes from one mutant 
containing an altered L4 protein were shown to bind 
erythromycin poorly and had a reduced peptidyltranBferase 
activity, interestingly, the distribution of polysomes in 
these cells waB unaltered by growth in the presence of the 
drug. Curiously, none of these features was found for 
ribosomes from another mutant which contained an altered L22 
(Wittmann et al., 1973). Mutants dependent on erythromycin 
for growth have also been isolated and studied (Dabbs, 1979; 
Sparling and Blackman, 1973; Wild, 1988). Protein L25 was 
found to be responsible for the dependence in one of these 
strains (Wild, 1988). it has also been shown that some of the 
revertants from this dependence mutation in Escherichia coli 
were altered in ribosomal subunit assembly and were missing 
protein L19 (Wild, 1988). In fact, several erythromycin 
dependent mutants have been described with either protein 
S20, Lll, L15, L28, L29, or L30 missing (Dabbs, 1979) .
13
Intersubunit interactions in erythromycin binding have 
been implied by the observation that 1*4 erythromycin- 
resistant mutants become sensitive to the drug if the genes 
for streptomycin or spectinamycin-resistance (affecting 
proteins S12 and S5) are present in the same cell as well 
(Apirion and Saltzman, 1974; Saltzman and Apirion, 1976).
Drug binding to the 50S subunit has also been shown to be 
dependent on the types of 3OS subunit proteins present. This 
suppression of drug-resistance suggests an interaction 
between the subunits in the action of the antibiotic. 
Altogether this information suggests that erythromycin 
binding and inhibition involves a collection of ribosomal 
components including 50S proteins L4, L15, L16, L22, 
specific 23S ribosomal RNA sequences and certain 
macromolecules of the 30S subunit.
Virtually all of the extensive work on erythromycin and 
related 50S inhibitors has focused on their mechanism of 
translational inhibition. With the exception of the 
suggestion by Vester and Garrett (1987) that erythromycin may 
stimulate 50S subunit degradation, effects on the formation 
or breakdown of the large subunit have not been investigated. 
This point seems worth considering since the 23S rRNA, and 
ribosomal proteins L4 and L22 are all involved in the 
earliest parts of SOS subunit assembly, interacting at the 5' 
end of the 23S rRNA (Herold and NierhauB, 1987) (Figure 3). 
Two observations suggest that erythromycin may have an 
additional effect on growing bacterial cells. It has been 
pointed out that the molar concentration of erythromycin
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Figure 3. Assembly Map of £. coll SOS Ribosomal Subunit.
The upper bar represents the 23S rRNA while numbered circles 
designate large ribosomal subunit proteins. Thiele arrows 
indicate strong binding and thinner arrows indicate weaker 
binding.
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tor 6SrRNA ta a g ru o n
(Herold and Nierhaus, 1987)
required to affect translation in vitro is significantly 
greater than the measured inhibitory concentrations in vivo 
(Corcoran, 1964), suggesting a second effect of the compound 
in cells. In addition, ribosomes from an erythrontycin- 
resistant mutant strain of Escherichia coli with an 
alteration in ribosomal protein L22 could still bind the 
antibiotic and showed normal peptidyltransferase activity. 
Both of these activities were altered in another resistant 
mutant with an L4 protein change (wittmann et al., 1973). 
These data Buggest that a different target for erythromycin 
has been effected in the L22 mutant strain compared with that 
in the L4 mutant strain.
When one considers the conplexity of the mRNA 
translation process, it seems apparent that molecular tools 
like erythromycin can be important in unraveling the process. 
The Escherichia coli ribosome with its 53 proteins and 3 
ribosomal RNAs no doubt has many nuances yet to be 
discovered. The main focus of previous genetic research into 
the mechanism(s) of erythromycin resistance has focused on 
23S rRNA alterations. Although certain ribosomal protein 
mutants (L4 (rplD) and L22 (rpiv)) have been shown to exhibit 
this phenotype, their examination has not been as extensive.
A complete understanding of the mechanism(s) is not likely to 
be forth coming without consideration of these types of 
mutants. For that reason, the erythromycin resistant mutants 
N281 and N282 were obtained from Dr. David Apirion (Apirion, 
1967). Hopefully this work will allow a better understanding 
of a small part of this process as well as to aide in the
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design of better and more effective antibiotics for the 
future. Key to these objectives is the development of a 
model for the mechanism(s) by which erythromycin produces its 
inhibitory effects on bacterial growth. This work describes 
the development of Buch a model.
Chapter 2 
Materials and Methods
Materials
Ampicillin, pancreatic deoxyribonuclease I (DNAse I), 
erythromycin, ethidium bromide, lincomycin, lysozyme, 
oleandomycin, 2,5-diphenyloxazole (PPO), ribonucleaBe 
(RNAse), spiramycin, and virginiamycin Ml were purchased from 
Sigma Chemical Corporation. Acrylamide, agarose, methylene 
bis-acrylamide, Triton x-100, and N,N,N’ ,N’ - 
tetramethylethylenediamine (TEMED) were purchased from 
BioRad. Acetic acid, mercaptoethanol, chloroform, 
ethylenediaminetetracetic acid (EDTA), isoamyl alcohol, 
isopropanol, trichloroacetic acid, and toluene were purchased 
from Fisher Scientific. Restriction enzymes and buffers, 
phenol, sucrose, and urea were purchased from International 
Biotechnologies, inc. Hydrolink Long Ranger gel was 
purchased from AT Biochemical, Inc. Coomassie Brilliant Blue 
R-250 stain was purchased from Kodak. All culture media used 
in this study were purchased from Difco Laboratories. 
Radioisotopes ([5,6-3H]-uridine (40.7 Ci/mmol), [N-methyl- 
14C]-erythronycin (54 mCi/mmol), and 35S-dATP (1355 Ci/mmol) 
were purchased from New England Nuclear Products. The Taq 
polymerase kit was purchased from Promega Corporation. 
Proteinase K was purchased from E.M. Biochemicals. Pyronine 
Y was purchased from Allied Chemical. The Sequenase 2.0 kit 
was purchased from United States Biochemical Corporation. 
Azithrorrrycin and clarithromycin were gifts from Pfizer and
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Abbott Laboratories respectively.
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Bacterial Strains and Plasmids 
All bacterial strains and recombinant plasmids used are 
described in Table 1.
Media
Bacterial strains were stored at -80°C in 1 ml aliquots 
of L broth containing 20% glycerol. Cells were grown in L 
broth or tryptone broth (TB). L broth consists of 10 g 
bacto-tryptone, 10 g Had, 5 g yeast extract, and 1.5 ml 1 N 
NaOH dissolved in l liter of deionized water (dHao). Tryptone 
broth contains 13 g tryptone and 7 g NaCl dissolved in 1 
liter of dH20 {Miller, 1972}. Plates were made with the same 
media containing 1.6% agar.
Methods
Growth Experiments
Small-scale growth experiments were done in a shaking 
water bath. Ten milliliters of L broth were inoculated with 
0.2 ml of an overnight culture in a 125 ml side-arm flask.
The cell density was determined using a Klett-Summerson 
colorimeter with a red {Number 66) filter. The appropriate 
drug was added at a cell density of 2 x I0a cells/ml. Large- 
scale growth experiments were done on a shaking platform in a 
Bally environmental room at 32°C. cell densities for these 
cultures were determined by reading the absorbance at 600 nm
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Table 1. Bacterial Strains and Recombinant Plasmids.
Strain Mo. Genotype Source
SK901 F", aroE+, malA", 
thi", ery6
Kushner et. al, 1977
N281 Hfr, mal+, thi+, 
eryR
Apirion, 1967
M282 Hfr, mal+, thi+, 
eryR
Apirion, 1967
Plasmid Genotype Source
pLF 1.0 l% Ecori fragment 
of Xfus2 subcloned 
into pBR325
Watson and Surzycki, 
1983
pLF 4.6 4.6% EcoRl fragment 
of Xfus2 subcloned 
into pBR325
Watson and Surzycki, 
1983
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in a Beckman Model 25 spectrophotometer.
Preparation of Competent Cells
This procedure was done according to the method of 
Silhavy et al. (1984). Cells were grown in L broth to an 
absorbance of 0.2 at 600 nm. The cells were then chilled on 
ice for 20 minutes followed by centrifugation at 6400 x g, 
for 20 minutes at 4°C in a Beckman JA-10 centrifuge. The cell
pellet was resuspended in 200 ml of cold 100 mM CaCl2. Next! 
the suspended cells were incubated on ice for 20 minutes and 
repelleted as before. Finally, the cells were resuspended in 
5 ml of cold 100 mM CaCl2, made 10% in glycerol and stored at 
4°C overnight. Competent cells were used immediately for 
transformation or frozen at -80°C for use later.
Bacterial Transformations
Transformation of competent cells followed the method of 
Silhavy et al. (1984). First, 0.5 ug of plasmid DMA (in a 
volume of 10 ul or less) was added to a 0.2 ml aliquot of 
competent cells in a 1.5 ml microfuge tube. The suspension 
was allowed to stand on ice for 1 hour, followed by a two- 
minute heat shock at 37°C. Next, the mixture was diluted with
1 ml of L broth and incubated for 1 hour at 37°C for 
phenotypic expression. The cells were pelleted in a 
microfuge and resuspended in o.l ml of L broth. Fifty 
microliters of the transformation mix was plated on an L 
broth plate containing 50 ug/ml of ampicillin and placed at
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37°C overnight to select for transformed cells.
Screening Transformants
Ampicillin-resistant colonies were picked from the 
overnight transformation plate and placed onto a second 
ampicillin plate. This plate was allowed to grow at 37°C 
overnight and then replica plated onto a third ampicillin 
plate containing 500 ug/ml erythromycin. Complemented mutant 
cells are unable to grow at this concentration of 
erythromycin, while noncomplemented mutants grow slowly. The 
complemented colonies were selected and then used to make 
freezer stockB.
Isolation of Plasmid DNA
Plasmid DNA. was isolated by one of two methods. The 
first method employed alkaline lysis and PEG precipitation 
steps. The second method involved a boiling miniprep 
procedure followed by further purification using a 
commercially available "glass milk" type DNA purification 
kit.
Method One. This miniprep procedure was provided by Dr. 
Phillip Musich (Musich and Chu, 1993). Cells containing the 
desired plasmid were used to inoculate 20 ml of L broth 
containing 50 ug/ml of ampicillin. The cultures were then 
incubated on a platform shaker at 32°C overnight. Cells were 
collected by centrifugation at 1,000 x g for 10 minutes. The
cell pellet was resuspended in 0.6 ml of SET buffer (20% 
sucrose, 50 mM Tris-HCl pH 8) by vortexing. The suspension 
was transferred to a 1.5 ml microfuge tube. The culture tube 
was then rinsed with an additional 0.7 ml of SET buffer and 
transferred to the microfuge tube. The cells were pelleted 
by centrifugation for 20 seconds in a microfuge. The 
supernatant was poured off and discarded. The remaining 
pellet was resuspended in the residual liquid by vortexing 
until creamy. The suspension was mixed with 250 ul of SET 
buffer by vortexing. Cell lysis was initiated with the 
addition of 0.5 ml of alkaline lysis solution (0.2 N NaOH and 
1% SDS) and gentle mixing by tube inversions. Lysis was 
canqpleted by incubation at 65°C for 30 minutes with one or two 
tube inversions during the incubation. Following incubation, 
375 ul of 5M KCl, pH 5.2, was added with gentle mixing.
Next, the tubes were placed on ice for at least 20 minutes, 
insoluble material was pelleted by spinning the tubes in a 
microfuge for 15 minutes. The supernatant was transferred to 
a clean tube and spun for an additional 10 minutes to assure 
that all debris was removed. Then the supernatant was 
transferred to a clean microfuge tube and 300 ul of 27% 
polyethylene glycol (PEG) in 3.3 M NaCl was added and mixed 
by inversions. The tubes were placed on ice for 2 hours and 
the DNA precipitate was pelleted in a microfuge by spinning 
15 minutes. The pellet was washed with 1 ml 70% ethanol and 
repelleted as before. The pellet was then dried in a speed 
vac and redissolved in 200 ul of T^E* (10 rrtM Tris-HCl pH 8.4,
1 mM EDTA). A 5 ul aliqout of DNA was removed and examined
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for purity on an agarose gel of the appropriate percentage.
To further purify the DNA., 200 ul of 5 M anmonium acetate and 
400 ul of isopropanol were added with mixing by inversion.
The samples were chilled on ice for 20 minutes followed by a 
15 minute spin in a microfuge. The DNA pellet was washed 
twice with 1 ml aliquots of 70% ethanol and repelleted as 
before. The pellet was vacuum dried and resuspended in the 
appropriate volume of TjEq^  (l mM Tris-HCl pH 8.4, 0.1 mM 
EDTA) .
Method Two. The boiling miniprep and "glass milk* 
portions of this method were preformed according to the 
procedures provided in an Elu-Quik DNA purification kit 
purchased from Schleicher and Schuell. CellB containing the 
desired plasmid were used to inoculate 5 ml of L broth 
containing 50 ug/ml of an$>icillin. A 1.5 ml portion of the 
culture was transferred to a 1.5 ml microfuge tube and 
pelleted in a microfuge for 1 minute. The supernatant was 
removed and the pellet was resuspended in 350 ul of STET 
buffer (0.1 M NaCl, 10 irM Tris-HCl pH 8.0, 1 m  EDTA pH 8.0 
and 5% Triton X-100). To this, 25 ul of freshly prepared 
lysozyme (10 mg/ml in 10 mM Tris-HCl pH 8.0) was added and 
mixed by vortexing. The cells were lysed by placing the tube 
in a boiling water bath for 40 seconds. Cell debris was 
pelleted by centrifugation in a microfuge for 10 minutes.
The supernatant was placed in a clean 1.5 ml microfuge tube 
and the plasmid purification process was continued using the 
Elu-Quik DNA purification kit and the procedure provided by
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the manufacturer. Purified DNA was placed in an appropriate 
volume of T1E0ii and examined for purity as described in the 
previous section.
Isolation of Genomic DMA
Genomic DNA. was prepared according to the method of 
Ausubel et al. (1969). First, a 5 ml overnight culture grown 
in L broth at 37°C was divided into three 1.5 ml microfuge
tubes. Next, the cells were pelleted by centrifugation for 2 
minutes in a microfuge and resuspended in 567 ul of T^E^ To 
this, a volume of 30 ul of 10% SDS was added, followed by 3 
ul of 20 mg/ml proteinase K. The sample was then mixed by 
inversion and incubated at 37°C for 1 hour. Following 
incubation, 100 ul of 5 M NaCl and 80 ul of CTAB (0.7 M NaCl, 
10% hexadecyltrimethyl ammonium bromide) were added, and the 
tubes were placed in a 65°C water bath for 10 minutes. Next, 
the sample was extracted with an equal volume of 
chloroform:isoamyl alcohol (24:1) by inverting the tube 
repeatedly. The sample was separated into two phases by 
centrifugation for 4 minutes in a microfuge. The aqueous 
layer waB transferred to a fresh microfuge tube and extracted 
again with an equal volume of phenol: chloroform: isoairyl 
alcohol (25:24:1). The DNA-containing aqueous phase was 
removed and precipitated by the addition of 0.6 volumes of 
isopropanol. Next, the DNA was spooled from the 
precipitation interface onto a sealed Pasteur pipet and 
transferred into 1 ml of 70% ethanol for washing by
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inversion. The DNA was pelleted by centrifugation in a 
microfuge for 10 minutes and rewashed a second time aB 
before. Finally, the DNA pellet was dried in a speed vac and 
resuspended in 100 ul of Concentration and purity
were determined by measuring the absorbance at 260 and 280 
ran.
Polymerase Chain ReactiontPCRl
The nucleotide sequence of the S10 operon was retrieved 
from Genebank (accession number X02613) (Zurawski and 
zurawski, 1985). The sequence was examined for suitable 
oligonucleotide primers using the oligonucleotide analysis 
program "Oligo* (National Biosciences). The program 
identified two sets of forward and reverse primers 
appropriate for the amplification of the rpiv and rplD genes. 
The sequences of the primers were sent to Dr. Kenton L.
Lohman (Southwest Foundation for Biomedical Research; San 
Antonio, Texas) for synthesis. The sequences of the rpiv 
forward and reverse primers were 5'-CGG TGG AAA GCG GAG ACA
AGA AGC C-3' and 5'-ACC AGT TTT GCG TCC AGT TCA GGC T-3',
respectively. The sequences of the rplD forward and reverse 
primers were 5'-GGC AAG AAA ATG GCA GGT CAG ATG G- 3' and 5'-
TTC CAT CGC AGT AGA CGC TTT TTC A- 3', respectively. Upon
arrival the primers were cleaned by n-butanol extraction.
The concentrations of the rpiv primers were determined by Dr. 
Phillip Musich (ETSU) using agarose gel analysis with known 
DNA standards. The concentrations of the rplD primers were 
determined by measuring their absorbance at 260 ran. PCR
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reactions were carried out £or the rpiv gene with the wild 
type control strain and the rpiv mutant strain (N281), using 
the appropriate primers. Reactions for the rplD gene were 
performed using the same control strain and the rplD mutant 
strain (N282) in conjunction with their designated primers. 
EnzymeBi nucleotides, and buffers were purchased as a kit 
from Promega. The following ingredients were placed into a 
0,5 ml microfuge tube : 1.0 ug genomic DNA, 20 ul of 10X 
buffer (0.5 M KC1, 0.1 M Tris-HCl pH 8.4, 25 nM MgCl2, 1 mg/ml 
gelatin, 0.1% Tween 20, and 0.1% NP-40), 4 ul of dNTP mix 
(from 10 mM solutions), 40 pmol each of the forward and 
reverse primers, 4 ul of sequencing grade Taq polymerase (10 
Units) and dH20 to a final volume of 200 ul. Twenty-five 
microliters of paraffin oil was then layered on top of the 
sample to prevent evaporation of sample during the reaction 
process. The Bamples were placed in a Precision Scientific 
GTC-l thermal cycler for thirty cycles under the conditions 
of a predetermined PCR program scheme (Ehrlich et al., 1988). 
The program consisted of the following steps in order of 
occurrence: denaturation at 94°C for 2 minutes, annealing of 
primers to target DNA at 55°C for 2 minutes, and 
polymerization at 72°C for 5 minutes. Three microliters of 
the PCR reaction product from each set of reactions was 
examined on a 1.14% agarose gel for spurious bands. Finally, 
the remaining portion of each reaction was run on another 
1.14% agarose gel and the desired fragment electroeluted from 
the gel in to purify the PCR products from contaminating
fragments, nucleotides and primers.
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Electroelution of PCR Products from Agarose Gels
PCR products were electrophoresed in a 1.14% agarose gel 
containing 0.5 ug/ml ethidium bromide. The DNA bands of 
interest were located by fluorescence using a UV 
transilluminator. The bands were then excised with a razor 
blade and placed into the elution wells of an electroelution
apparatus (International Biotechnologies, Inc.) Then, 150 ill
of 7.5 M ammonium acetate/0.01% xylene cyanol solution was 
placed into the V-shaped collection channels of the apparatus 
and the DNA was eluted from the gel slice at 50 volts for 1 
hour in tae buffer (40 nM TriB acetate, 2 nM EDTA}. The 
eluted DNA in the ammonium acetate/xylene cyanol solution was 
recovered by alcohol precipitation.
Agarose Gel Electrophoresis
Electrophoresis was carried out in a Hoefer submarine 
minigel apparatus according to the procedure adapted by 
ManiatiB et al. (1982). The gel solution consisted of an 
agarose concentration appropriate to produce fragment 
resolution and 30 ml of running buffer. The running buffer 
was comprised of 89 nM Tris-borate and 2 nM EDTA, pH 8.3 
(TBE). The agarose solution was heated in a boiling water 
bath until melted, cooled to 55°C, and poured into a gel mold 
containing an 8 well comb (well dimensions = 1 x 6 x 8 mm). 
After the gel had solidified, the comb and gel tray were
28
removed from the molded gel and samples were loaded. The gel 
was then electrophoresed at 50 volts until the Orange 6 
tracking dye reached the desired point, in some instances 
ethidium bromide was added to the gel and running buffer 
solution at a concentration of 0.5 ug/ml. Otherwise, the 
gels were stained in a solution of 0.5 ug/ml ethidium bromide 
following the electrophoresis. DNA bands were visualized by 
placing the gel on a UV transilluminator. Photographs were 
taken using a Polaroid MP-4 Land camera, a red #23A UV filter 
and Polaroid type 55 film.
Restrictton Enzyme Digests
Restriction digests of plasmid DNA were performed 
according to the method of Maniatis et al. (1982).
Restriction enzyme buffer waB added to the DNA and diluted to 
a final concentration of IX with water. The DNA was digested 
using 10 units of the appropriate restriction enzyme per 
microgram of DNA. The digests were incubated at 37°C 
overnight. Samples were then heated at 70°C for 5 minutes to 
inactivate the enzyme. The digests were then examined on an 
agarose gel of the appropriate percentage.
DNA Sequencing bv Primer Extension
PCR products from the rpiv and rplD genes were sequenced 
using a dideoxynucleotide chain-termination method (Sanger et 
al., 1977). This procedure was performed using materials and 
instructions provided in a Sequenase 2.0 DNA sequencing kit 
purchased from united states Biochemical corporation. The
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PCR products and primers were generated as described above. 
Primers for sequencing the rplD gene were the same as those 
used to generate the PCR product, but were used individually. 
However, a second set of primers (15-mers) were generated by 
Dr. Kent Lohman for sequencing the rpiv gene. The sequence 
of this forward primer was 5' -GCG ACG CTG CTG ATA- 3'. The 
sequence of the reverse primer was 5f-CCC AGG CGA ATA CCA- 
3'.
Templates and primers were annealed according to the 
method of Ausubel et al. (1989). The annealing reactions 
consisted of 1 ug of PCR product, 1 pmol of primer (either 
forward or reverse), and 2 ul of Sequenase reaction buffer 
brought to a final volume of 10 ul with water. The labeling 
mix was diluted 5-fold with water and the enzyme was diluted 
1:8 with the provided dilution buffer. One microliter of 35S- 
dATP was used per reaction set. The reactions were conducted 
according to the Sequenase protocol provided by the 
manufacturer. Sanples were preheated to 75°C for two minutes 
and one-half of the reaction volume was loaded onto either a 
6% or 8% polyacrylamide gel containing 42% urea or a 6% 
Hydrolink Long Ranger gel in 89 iflM TBE (lx) poured using 0.4- 
0.8 mm wedge spacers. The sequencing buffer was IX TBE. The 
sequencing gel was pre-run at, constant power (45 watts) for 
30 minutes. The saiqples were loaded and electrophoresed for 
an appropriate time, then the second half of the reaction 
volume was loaded and electrophoresed to the desired end 
point. Running and loading timeB were dependent on the 
sequence position which was to be read. Position was
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determined by following the migration of the xylene cyanol 
and bromophenol blue marker dyes. After electrophoresis was 
completed, the gel was removed and placed on Whatman 3 mm 
filter paper, covered with plastic wrap, and dried using a 
gel drier apparatus. Autoradiograms were prepared from the 
dried gel by exposure to Kodak diagnostic X-GMAT AR film for 
periods of 3 days or more, developed and read manually.
70S Ribosome Isolation
Ribosomes were isolated according to Traub et al.
(1971). A milliliter of overnight culture was used to 
inoculate 1 liter of L broth. Cultures were grown at 32°C 
until the absorbance at €00 run reached l.o. The cells were 
pelleted at 8700 x g at a temperature of 4°C for 20 minutes. 
The cell pellets were washed with 10 ml R-buffer (10 nM Tris- 
HCl pH 7.6, 10 mM magnesium acetate, 50 mM NH4C1, 0.2 mM 
mercaptoethanol (ETSH)), repelleted and stored frozen at -80°C 
until used. Upon thawing, the cells were resuspended in 5 ml 
of R-buffer. Freshly prepared lysozyme was added to a 
concentration of 30 ug/ml, followed by a 15 minute incubation 
at room terrperature. The suspension was then frozen in an 
ethanol/dry ice bath and thawed in warm water 3-4 times until 
cell lysis was canplete. Next, pancreatic DNAse I (l mg/ml 
in 10 mM Tris-HCl pH 7.9, 10 mM MgS04) was added to a 
concentration of 10 ug/ml. Lysates were then allowed to 
stand for 10 minutes until digestion of DNA was complete.
Cell debris was pelleted at 12,000 x g for 20 minutes at 4°C.
The supernatant was layered onto 5 ml of ribosome wash I (10% 
sucrose, 2 M NH4Cl, 10 nM MgClz, 10 nM Tris-HCl pH 7.9) and 
spun at 134,800 x g, for 4 hours, at 4°c in a Beckman model 
L5-65 ultracentrifuge. The ribosomal pellets were 
resuspended in 1 ml R-buffer overnight at 10°C. Any insoluble 
contaminants were removed by a 2 minute centrifugation in a 
microfuge. Ribosomal purity and concentration were 
determined by measuring the absorbance ratio at 260 and 280 
nm. The ribosomal pellets were stored frozen at -80°C.
Ribosomal Protein isolation
Ribosomal proteins were isolated using an acetic acid 
extraction method (Hardy et al., 1969). An aliquot of 
ribosomes equal to 20 a260 units was removed from the -80°C 
freezer and placed in a 1.5 ml microfuge tube for ribosomal 
protein extraction. To this, a one tenth volume of 1 M 
magnesium acetate and 2 volumes of acetic acid were added to 
extract the proteins and precipitate the rRNA. This solution 
was placed at 4°C and precipitation allowed to proceed for 2 
hours. Next, the rRNA was pelleted by centrifugation in a 
microfuge for 2 minutes. The supernatant was placed in a 
fresh microfuge tube and ribosomal proteins were precipitated 
with 5 volumes of cold acetone at -20°C for 4 hours 
(Barritault et al., 1976). Ribosomal protein was pelleted by 
spinning the saiqples for 5 minutes in a microfuge. The 
supernatant was removed and the protein pellet was allowed to 
dry inverted overnight. Finally, proteins were resuspended
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in the appropriate buffer for electrophoresis.
Two-Dimensional Polyacrylamide Gels
Ribosomal proteins were separated according to the 
method of Kenny et al. (1979). This method employs an acidic 
first-dimensional separation technique.
First -Dimension. Gel tubes measuring 12 cm in height 
and 2 mm in diameter were used for the first-dimension tube 
gel electrophoresis. The gel tubes were filled to a 10 cm 
mark with first-dimension separating gel containing 4% (w/v) 
acrylamide, 0.066% (w/v) methylene bis-acrylamide, 6 M urea; 
and 38 mM bis-Tris adjusted to a pH of 5.5 with acetic acid.
Gel polymerization was initiated by the addition of 1 |il of
N,N,N' ,N'-TEMED and 5 ul of 10% (w/v) amonium persulfate per 
milliter of gel solution. A flat interface was achieved by 
the addition of a 100 ul of water. After polymerization 
(approximately 20 minutes) the water was removed. Ribosomal 
proteins were then dissolved in 50 ul of first-dimension 
sample buffer containing 8 M urea, 40 mM mercaptoathanol, and 
0.1% (w/v) pyronine Y. The samples were loaded on top of the 
polymerized gels and the gels were placed in an 
electrophoresis apparatus containing 250 ml bis-Tris acetate 
at pH 3.7 (upper reservoir) and pH 7.0 (lower reservoir).
The proteins were then stacked at the gel-sample interface by 
electrophoresis at 0.5 milliamps per gel (constant current) 
for 30 minutes. Finally, the current was increased to 1 
milliamp per gel until 45 minutes after the tracking dtye ran
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off the gel {3.5-4 hours).
Second-Dimension. The second dimension electrophoresis 
was performed according to the method of Kaltschmidt and 
Wittmann (1970). The first-dimension tube gels were removed 
using a water filled syringe and positioned on top of freshly 
poured 18% slab gels. Second-dimension gel solution (pH 4.5) 
consisted of: 18% (w/v) acrylamide? 0.25% (w/v) methylene 
bis-acrylamide; 48 mM KOH; 6 M urea? 0.92 M acetic acid; and 
0.58% (v/v) TEMED. Slab gels were polymerized by the 
addition of 20 pi of 10% (w/v) amonium persulfate per
milliter of second-dimension gel solution. The gel slab was
14 cmx 12 cm x 2,5 m  and held approximately 30 ml of gel 
solution. The IX running buffer (pH 4.0) contained 140 g of 
glycine and 15 ml of acetic acid dissolved in 1 liter of 
water. The upper (cathode) and lower (anode) reservoirs 
contained IX (400 ml) and 0.33X (1200 ml) running buffer
respectively. Pyronine Y was used as the tracking dye. The
electrophoresis consisted of a 30 minute stacking at 40 volts 
followed by an increase to 100 volts (constant voltage) for
15 hours or until the tracking dye was approximately 2 cm 
from the bottom of the gel. Proteins were visualized by 
staining for l hour with 0.1% (w/v) Cocxnassie Brilliant Blue 
R-250, 50% (v/v) methanol, and 7% (v/v) acetic acid. Gels 
were destained in a solution of 10% (v/v) ethanol and 5%
(v/v) acetic acid until protein spots were visible against a
clear background. Photographs of stained gels were taken 
UBing a Polaroid mp-4 Land camera, Polaroid type 55 film, and
34
a #8 yellow filter.
Ribosomal Subunit Assembly Analysis
Assembly experiments were done according to the method 
of Champney (1979). Cells were grown in 10 ml of tryptone 
broth at 37°C on a shaker water bath to a Klett density of 20 
followed by addition of the desired antibiotic to test 
cultures. Next, the cells were labeled with 1 uCi 3H-uridine 
and 2 ug uridine per milliliter of culture 1 hour after the 
addition of the drug. Incubation continued to a Klett 
density of 100 for control cellB or until growth stopped in 
cultures containing antibiotics (8-10 hours). After growth 
was complete, the cells were collected by centrifugation at 
2000 x g for 20 minutes. The cell pellet was resuspended in 
0.2 ml S buffer and 30 ug lysozyme was added. S buffer 
consists of 10 ium Tris-HCl, pH 7.6, 0.5 irM magnesium acetate, 
50 inM NH4C1, and 6 mM mercaptoethanol. The suspension was 
then frozen in an ethanol/dry ice bath and thawed in warm 
water 2-3 times until cell lysis was complete. After lysis 
was complete, 10 ug of pancreatic DNAse I was added and the 
cells were placed on ice for 5 minutes. Cell debris was 
removed by centrifugation at 12,000 x g for 15 minutes at 4°C. 
The supematantB were then layered onto 5-20% sucrose 
gradients in S buffer (no mercaptoethanol) and centrifuged at 
189,000 x g for 2 hours at 4°C in a swinging bucket rotor (SW
50.1). Typically, 30-35 fractions of three drops each were 
collected and diluted with 1 ml of water. The absorbance at
260 nm was measured for each fraction. An equal volume of 
10% TCA and 100 ug of BSA were added and the precipitated 
materials were collected on Whatman type GF/A glass 
microfibre filter by vacuum filtration. Finally, the filters 
were dried and counted in in a Beckman LS 3801 scintillation 
counter. The 3H counting efficiency was 82.0% in a toluene
0.25% (v/v) PPO solution. The optical density and 
radioactivity in counts per minute tcpm) from an equal number 
of fractions surrounding both the 50S and 30S peaks were used 
to calculate the specific activity ratios for each gradient.
Ribosomal Subunit Degradation Analysis
Cells were grown in 8 ml of tryptone broth at 37°C on a 
shaker water bath to a Klett density of 60 in the presence of 
0.4 uCi 3H-uridine per milliliter of culture. The cultures 
were subsequently chased with 10 ug uridine per milliter of 
culture and split into two 4 ml cultures. An additional 6 ml 
of tryptone broth and erythromycin at 75 ug per milliliter of 
sanple were added. Incubation continued to a Klett density 
of 100 for control cells or until growth stopped in the 
erythromycin culture (8-10 hours). After growth was 
canplete, the cells were collected by centrifugation at 2000 
x g for 20 minutes. Subunits were collected and counted as 
previously described for ribosomal subunit asseirbly analysis. 
The optical density and radioactivity in counts per minute 
(cpm) from an equal number of fractions surrounding both the 
50S and 30S peaks were used to calculate the specific
activity ratios for each gradient.
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Ervthromvcin Binding Reaction
Erythromycin binding reactions were performed 
essentially according to the method of Teraoka (1970).
Binding reactions took place in 125 pi of reaction mixture 
containing 3-4 A260 units of 70S ribosomeB, 40,000 cpm [14C] - 
erythromycin, 50 mM Tris-HCl pH 7.8, 16 mM magnesium acetate, 
and 80 nW KCl. The samples were incubated at 37°c for 15 
minutes, immediately immersed in an ice bath and diluted with 
3 ml of cold wash buffer. WaBh buffer contained 25 mM Tris- 
HCl pH 7.8, 60 mM KCl, and 20 mM magnesium acetate. The 
diluted mixture was then vacuum filtered onto a 0.45 um 
Millipore type HAWP filter prewetted with wash buffer. The 
filters were then washed five times with wash buffer, dried, 
and counted as previously described for ribosomal subunit 
assembly analysis. The [MC] counting efficiency was 91.6%.
Chapter 3 
Results
Experimental Results
Two-dimensional Electrophoresis
Previously, Wittmann et al. (1973) found that mutants 
N281 and N282 contained alterations in ribosomal proteins L22 
and L4 respectively. These findings were initially based on 
genetic mapping studies. Later, two-dimensional 
electrophoretic analysis of the ribosomal proteins of the 
mutants revealed that strain N281 had an altered 
electrophoretic mobility for protein L22. The other mutant 
did not appear to exhibit any clear mobility changes in the 
gel system used. However, the researchers were able to 
confirm the previous mapping results (which implicated 
protein L4) using a chromatographic separation technique.
That technique revealed that protein L4 of mutant N282 had an 
altered elution profile from a carboxymethyl cellulose column 
at pH 5.6 (Osawa et al., 1969). When conpared to the pH 8.6 
first-dimension separation used in the previous 
polyacrylamide gel electrophoresis, it seemed likely that the 
L4 protein from this mutant might have a detectably altered 
mobility if the electrophoresis was at or near pH 5.6. The 
two-dimensional electrophoresis procedure of Kenny et al. 
(1979) employs a first-dimension separation at pH 5.5. 
Therefore, it seemed likely that the L4 protein from this 
mutant (as well as the L22 mutant) might be better resolved
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in that gel system.
To investigate this possibility, ribosamal proteins from 
both mutants were electrophoresed using the separation method 
of Kenny et al. (1979). As Figures 4A and B indicate, the 
mutant proteins from each strain showed a significantly 
decreased electrophoretic mobility in the first-dimension gel 
at pH S.5. This indicates that the altered protein from each 
mutant has a more negative overall charge at pH 5.5 than do 
the wild type proteins from strain SK901 (Figure 5). In 
addition, the mobility of L4 was normal in the L22 mutant 
strain as was the L22 protein in the L4 mutant strain (Figure 
4).
Sequencing the rolv and rnlD genes
In order to deteimine the exact nature of the mutation 
responsible for erythrontycin resistance in these mutants it 
was necessary to sequence the altered genes. Therefore, the 
rpiv (L22) and xplD (L4) genes were anplified from the 
genomic DNA isolated from the mutant and wild type strains 
using the (PCR) and a series of oligonucleotide primers 25 
nucleotides in length. The L22 and L4 genes were contained 
in 926 bp and 846 bp PCR products, respectively (Figures 6 
and 7). Purification of products away from spurious bands, 
primers and nucleotides was accomplished by electrophoresis 
on a 1.0% agarose gel (Figure 8). The desired bands were 
then sliced from the gel and the DNA electroeluted.
The purified PCR products were then sequenced to 
determine the mutational changes in the genes responsible for
Figure 4. two-dimensional electrophoresis of mutant 
RIBOSOMAL PROTEINS. Ribosomal proteinB from strains N282 (A) 
and N281 (B) separated by the electrophoretic method of Kenny 
et al. {1979). Arrows indicate the positions of both wild 
type (N) and mutant (M) ribosomal proteins.
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Figure 5. TWO-DIMENSIONAL ELECTROPHORESIS OF WILD TYPE 
RIBOSOMAL PROTEINS. ElectrophoreBis of ribosomal proteins 
from £. coli strain SK901 (Control) by the method of Kenny et 
al. (1979). Arrows indicate the position of wildtype L4 and 
L22 proteins.
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Figure 6. SEQUENCE OF rplV PCR PRODUCTS. The positions of 
primers used for PCR amplification (l»22 F-l and R-l) and 
sequencing of the rplV gene (D22 F-2 and R-2) are indentified 
by parallel lines. The wild type sequence indicated below is 
in accordance with that reported by Zuraweki and Zurawski 
(1985).
L22_ F-l
1 CGGTGGAAAG CGGAGACAAG AAGCCCCTGC GCACFK3GTC CCGTCGTTCA
51 ACGATCTTTC CTAACATGAT CGGTITGACC ATOGCTGTCC ATAATGGTCG
101 TCAGCACGTT CCGGTATTIG TAACCGACGA AATCGTTGGT CACAAACTGG
151 GTQAATTCGC ACCGACTCGT ACTTATCGCG GCCACGCTGC TGATAAAAAA
1*22 F-2
201 GCGAAGAAGA AATAAGGTAG GAGGAAGAGA TGGAAACTAT CGCTAAACAT
251 CGCCATBCTC GTTCTTCTGC TCAGAAGGTT CGCCITGTTG CTGACCTGAT
301 TCGCGGTAAG AAAGTGTCGC AGGCTCTGGA TATTTTGACC TACACCAACA
351 AGAAAGCGGC TGTACTGGTC AAGAAAGTTC TGGAATCTGC CATTGCTAAC
401 GCTGAACACA ACGATGGCGC TGACATTGAC GATCTGAAAG TTACGAAAAT
451 TTTCGTAGAC GAAGGCCCGA GCATGAAGOG CATTATGCCG CGTGCAAAAG
501 GT0GTGCAGA TCGCATCCTG AAGCGCACCA GCCACATCAC TGTGGTTGTG
551 TCCGATCGCT GAGACTCTGG AGACTAGCAA TGGGTCAGAA AGTACATCCT
L22.:R z2
601 AATGGTATTC GCCTGGGTAT TGTAAAACCA TGGAACTCTA CCTGG7TTOC
651 GAACACCAAA GAATTCGCTG ACAACCTGGA CAGCGATTFP AAAGTACGTC
701 AGTACCTOAC TAAGGAACTG GCTAAAGCGT CCGTATCTCG TATCGTTATC
751 GAGCGTCCGG CTAAGAGCAT CCGTGTAACC ATTCACACTG CTCGCCCGGG
801 TATCGTTATC GGTAAAAAAG GTGAAGACGT AGAAAAACTG CGTAAGGTCG
851 TAGOGGACAT CGCTGGOGTT CCTGCACAGA TCAACATCGC CGAAGTTCGT
L22 R-l
901 AAGCCTGAAC TGGACGCAAA ACTGGT
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Figure 7. SEQUENCE OF rplD PCR PRODUCTS. The positions of 
primers used for PCR amplification and sequencing of the rplD 
gene {L4 F and R) are indicated by parallel lines. The wild 
type sequence indicated below is in accordance with that 
reported by Zurawski and Zurawski (1985).
L4 F
1 GGCAAGAAAA TGGCAGGTCA GATGGGTAAC GAACGTGTAA COGTTCAGAG
51 CCTTGACGTA GTACGCGTTG ACGCTGAGCG CAACCTGCTG CTGGTTAAAG
101 GTGCTGTCCC GGGTGCAACC GGTAGCGACC TGATCGTTAA ACCAGCTGTG
151 AAGGCGTAAG GAGATAGCAA TGGAATTAGT ATTGAAAGAC GCGCAGAGCG
201 CGCTGACTGT TTCOGAAACT ACCTPCGGTC GTGATTTCAA CGAAGCGCTG
251 GTTCACCAAG TTGTTGTrGC TTATGCAGCT GGTGCTCGTC AGGGTACTCG
301 TGCTCAGAAG ACTCGTGCTG AAGTAACTGG ttcoggtaaa AAACCGTGGC
351 GCCAGAAAGG CACOGGCCGT GCGCGTTCTG GTTCTATCAA GAGCCCGATC
401 TGGCGTTCTG GTGGCGTGAC CTTTGCTGCT CGTCCGCAGG ACCACAGTCA
451 AAAAGTTAAC AAGAAAATGT ACCGCGGCGC GCTGAAAAGC ATCCTGTCCG
501 AACTGGTACG TCAGGATCGT CTGATCGTTG TCGAGAAGTT CTCTGTAGAA
551 GCGCCGAAAA CTAAGCTGCT GGCACAGAAA CTGAAAGACA TGGCTCTGGA
601 AGATGTGCTG ATCATCACCG GTGAGCTGGA CGAAAACCTG TTCCTGGCTG
651 CGCGCAACCT GCACAAGGTT GACGTACGCG ATGCAACTGG TATCGACCCG
701 GTTAGCCTGA TOGCCTTOGA CAAAGTCGTA ATGACTGCTG ATGCTGTTAA
751 GCAAGTTGAG GAGATGCTGG CATGATTCGT GAAGAACGTC
i,4 n
TGCTGAAGGT
801 GCTGCGTGCA CCGCACGTPT CTGAAAAAGC GTCTACTGCG ATGGAA
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Figure 8. PURIFICATION OF PCR PRODUCTS. A three microliter 
aliquot oC each PCR reaction was examined on a 1% agarose 
gel. Lanes 1-2: PCR products obtained from the
amplification of the rplV (L22) geneB of strains N281 and 
SK901 respectively. Lanes 4-5: PCR products amplified from
the rplD (L4) genes of strains N282 and SK901 respectively. 
Lane 3: Commercially available DNA size standards obtained
from Bio Ventures, Inc.
1 2 3 4 5
h « i o o o
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conferring erythromycin resistance. The rplD sequence of 
strain N282 revealed an A->G transition mutation in the first 
position of codon 63 (Figure 9A). This change would result 
in a Lys -> Glu change in the L4 protein and would account 
for the reduced gel mobility of the mutant protein at pH 5.5. 
Surprisingly, the rplV gene of strain N281 revealed a 9 bp 
deletion eliminating codons 82-84 in the gene and resulting 
in the loss of the tripeptide sequence Met-Lys-Arg from the 
L22 protein (Figure 9B). This loss would reduce the mobility 
of the protein at pH 5.5, similar to that of the L4 
alteration. Notably, a 4 bp direct repeat (GCAT) was found 
in the wild type sequence flanking the L22 deletion site.
This may be indicative of some type of secondary structure 
(i.e. stem-loop) participating in the deletion of the 
effected sequence.
Complementation Experiments
Antibiotic sensitivity is well known to be genetically 
dominant to resistance in bacterial cells which are 
merodiploid for the resistance gene (Nomura and Engbaek
1972). In order to examine this phenomenon as it relates to 
these mutants, strains N281 and N282 were transformed with 
plasmids pLF 1.0 and pLF 4.6, respectively. Each of these 
plasmid constructs are derived from pBR325. Plasmid pLF 1.0 
contains the L22 gene on a 0.5 kb EcoRX restriction fragment 
of bacteriophage Afus2 (which contains the E. coll S10
operon). Therefore, pLF 1.0 is capable of complementing 
mutations in the gene for protein 122 (Figure 10). In
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Figure 9. dna AND RIBOSOMAL PROTEIN SEQUENCE changes in 
MUTANTS N282 and N281. (A) The Lys to Glu alteration, found
in the mutant L4 (N282) protein is highlighted in bold. (B) 
The Met-Lys-Arg sequence deletion in the L22 mutant, N281 is 
indicated in bold and the two 4-bp repeats (GCAT) are double 
underlined.
A
60 65
SK901 L4 -Trp-Arg-Gln-Lya-Gly-Thr-Gly-
SK901 rplD -TGG CGC CAG AAA GGC ACC GGC-
N282 L4 -Trp-Arg-Gln-Glu-Gly-Thr-Gly-
N282 rplD -TGG CGC CAG GAA GGC ACC GGC-
B
80 85
SK901 1*22 -Pro-Ser-Met-Lys-Arg-Ile-Met-
SK901 rplV -COG AGO ATG AAG CGC ATT ATG-
N281 1.22 -Pro-Ser-ile-Met-
N281 rplV -CCG AGC ATT ATG-
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Figure 10. ORIGIN OF pLF PLASMID INSERTS. Map of the E- 
£Oli S10 ribosomal operon contained in the Xfus 2 genome.
Arrows indicate the EcoRl sites used to generate the pLF 1.0 
and pLF 4.6 inserts used for complementation of the rplD and 
rplV genes.
1
S10 Operon
tfAViV
P S10 S10 L3 U: L23 L2 SI9 122 S3 LI6 L29 SI 7VAv.v/j
T T T
2.3Kb 0.5Kb
pLF 4.6 pLF 1.0
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addition, mutations which occur in the gene for protein L4 
can be complemented using plasmid pLF 4.6, which contains the 
L4 gene on a 2.3 kb EcoRI fragment of the Sio operon (Figure 
10).
The growth rates of the mutant cells with and without 
coirplementing plasmids were measured in the presence and 
absence of erythromycin. As Table 2 indicates, both mutant 
strains showed a reduced rate of growth with increasing 
concentrations of erythromycin. The mutants grew about 2.5 
times more slowly in the presence of 600 ug/ml of 
erythronycin. Each complemented strain became more sensitive 
to erythromycin in the presence of the wild type gene. N281 
(pLF 1.0) grew 7.5 times more slowly at this same final 
concentration, while N2B2 (pLF 4.6) grew 3.7 times more 
slowly. These results are consistent the known dominance of 
erythromycin sensitivity to resistance in merodiploid cells 
(Nomura and Engbaek, 1972). However, N281 (pLF 1.0) was more 
affected by higher concentrations of the drug compared with 
N281 than was N282 (pLF 4.6) compared with its plasmid-free 
parent N282.
Since wild type cells will not grow at an erythromycin 
concentration of 300 ug/ml or greater (Apirion, 1967) these 
results indicate both mutant and wild type ribosomes are 
being assembled in complemented mutants. It seemed likely 
therefore, that the differences in the degree of growth 
inhibition between the two complemented mutants might be 
reflected in differing amounts of mutant protein found under 
each condition for each complemented mutant. To test this
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Table 2. Growth Rates o£ Mutant and Plasmid-Complemented 
Cells in the Presence and Absence of Erythromycin.
Strain
Erythromycin (ug/ml)
_Q_ iQjQ m .
M2 81 45 60 90 105
N281 (pLFl.O) 40 85 160 300
N282 45 55 75 115
N282 (pLF4.6) 35 65 70 130
Data points in the table above indicate doubling times in 
minutes.
hypothesis each complemented mutant was grown in either the 
presence or absence of 300 ug/ml of erythromycin. Ribosomes 
were collected from the cells and their proteins were 
examined on two-dimensional polyacrylamide gels (Figures U A ­
DI. in each instance mutant protein predominated in the 
presence of the antibiotic, while wild type protein was most 
abundant in the absence of the drug. However, as Table 3 
indicates, the ratios between mutant and wild type protein 
were not the same for each of the merodiploids. These 
findings are quite consistent with the differences in growth 
rate found between the two complemented mutants obtained in 
the previous experiment (Table 2},
One possible explanation for these differences is that 
plasmid copy number might differ depending on the type of 
growth conditions used (i.e. erythromycin present or absent). 
In order to examine this possibility, plasmidB were recovered 
from equal numbers of each of the complemented cells and cut 
with EcoRl to release the complementing inserts (Figure 12). 
Image analysis of the gel negative was then used to compare 
the amount of plasmid present under each growth condition 
(Table 4). These analyses revealed essentially no 
differences in plasmid copy number between a given 
merodiploid grown tinder either condition. This indicates 
that differences in incorporation of mutant versus wildtype 
protein are real and not a phenomenon resulting from plaBmid 
copy number changes found under the two conditions.
The percent of [14C] - erythromycin binding to 70S 
ribosomes was used to obtain another estimate of the ratio of
Figure 11. TWO-DIMENSIONAL ELECTROPHORESIS OF RIBOSOMAL 
PROTEINS FROM COMPLEMENTED CELLS. (A-B) Enlargement of the 
L22 region of a gel for ribosomal proteins isolated from N281 
(pLF 1.0) cellB grown in the presence (A) and absence (B) of 
erythromycin (300 ug/ml). (C-D) Enlargement of the Li region
of a gel for ribosomal proteins isolated from N282 (pLF 4.6) 
cells grown in the presence (C) and absence (D) of 
erythronycln (300 ug/ml). Relative positions of the L4 and 
L22 proteins are indicated.
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Table 3. Quantitation o£ RiboBomal Proteins from 
Complemented Cells.
Strain + Plasmid WT L4 M L4 WT L22 M L22
N281 {pLF 1.0) (E) 37.7 62.3
N281 (pLF 1.0) (E) 36.1 63.9
N281 (pLF 1.0) (NE) 100 *
N281 (pLF 1.0) (NE) 100 *
Average (E) 36.9 ± x.13 63.1± 1.13
Average (NE) 100 ± o.oo *
N282 (pLF 4.6) (E) 12.7 87.3
N282 (pLF 4.6) (E) 19.6 80.4
N282 (pLF 4.6) (NE) 73.3 26.7
N282 (pLF 4.6} (NE) 73.0 27.0
N282 (pl«F 4.6) (NE) 69.0 31.0
Average (E) 16.2 ± 4.B8 83.8 i  4.8B
Average (NE) 71.8 1 2.40 28.2 1 2.40
(E) 300 ug/ml Erythromycin; (NE) No Erythromycin; * = Not 
Detected; Data for each complementented mutant is summarized 
from each section of the table aB an average value i  one 
standard deviation.
Figure 12. PLASMID ISOLATION FROM COMPLEMENTED CELLS. All 
plasmidB used for quantification were digested with EcoRl. 
Lanes 1*2: Plasmids pLF 1.0 (lane 1) and 4.6 (lane 2)
isolated from strain SK901. Lanes 3-4: Plasmid pLF 1.0
isolated from strain N281 grown in the absence (lane 3) and 
presence (lane 4) of erythromycin. Lanes 5-6: Isolation of
plasmid pLF 4.6 from strain N282 grown in the absence (lane 
5) and presence (lane 6) of erythromycin. The positions of 
the vector and insert bands are indicated.
1 2 3 4 5 6
-^Vector
4.6
- * 1.0
Table 4. Quantitation of Plasmid DNA from Complemented 
Cells.
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integrated Intensity
Strain + Plasmid V/i ratio
pBR325 Insert
SK901 (pLP 1.0) (NE) 0.257 0.092 2.793
SK901 (pLF 4.6) (NE) 0.277 0.119 2.328
N281 (pLF 1.0) (NE) 0.391 0.113 3.460
N281 (pLF 1.0) (E) 0.415 0.140 2.964
N282 (pLF 4.6) (NE) 0.317 0.138 2.297
N282 (pLF 4.6) (E) 0.358 0.186 1.925
NE = No Erythromycin,* E - 300 ug/ml Erythromycin; V/I Ratio ■ 
pBR325 intensity/insert intensity
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wild type versus mutant protein in the ribosomes from strain 
N282 (pLF 4.6) assembled under each condition. This was 
possible since N282 ribosomes have been reported to have no 
binding of the drug, while wild type and N281 ribosomes have 
stoichiometric binding of erythromycin {Wittmann et al.,
1973). As Table 5 demonstrates ribosomes from strain N282 
(pLF 4.6) grown under each condition bound the expected 
amounts of radiolabeled drug. This prediction was based on 
two-dimensional electrophoresis results obtained for the Bame 
ribosomes and binding data collected for ribosomes from 
strains SK901 and N282 alone. Since ribosomes from strain 
N282 showed no binding of the drug, the percentage of 
wildtype protein from cells grown under each condition 
(obtained from the electrophoresis results) was multiplied by 
the percentage of erythromycin binding for wildtype 
ribosomes. This allowed a drug binding prediction to be made 
for ribosomes isolated from complemented cells grown under 
both conditions.
Ribosomal Degradation Analysis
Virtually all of the extensive work on erythromycin has 
centered on its mechanism of translational inhibition. The 
observation that the molar concentration of erythromycin 
required to affect translation in vitro is significantly 
greater than that in vivo (Corcoran, 1984) adds support to 
the concept of a second inhibitory mechanism. The 
complementation work done in this project supports such a 
hypothesis as well. Recently, Vester and Garrett (1987) have
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Table 5. t14C]-Erythromycin Binding to 70S Ribosomes.
Strain 2D Gels 
WT / M
% Erythromycin 
Bound
Predicted
Binding
SK901 100 / 0.0 77.0 + 1.08 NA
N281 0.0 / 100 64.5 ± 3.22 1 NA
N282 0.0 / 100 0.0 ± 0.00 NA
N282 (4.6) (NE) 71.8/28.2 49.7 ± 2.33 55.3
N282 (4.6) (E) 16.2/83.8 0.0 + 0.00 12.5
WT = percent wild type protein; M *= percent mutant protein;
NA - not applicable; % Erythromycin Bound = pmol [14C] - 
erythromycin bound/ pmol 70S ribosome x 100; A prediction of 
the binding percentage for complemented strains was 
calculated by multipling the percent wildtype L4 found in 2D 
gels by the percent erythromycin binding for SK901 ribosomes. 
All binding percentages represent an average of three points t  
one standard deviation.
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proposed that erythromycin may stimulate 50S subunit 
degradation. If true, this would represent a secondary 
mechanism capable of explaining these observations.
In order to examine this possibility, ribosomes in wild 
type cells were prelabeled with [3H] uridine and then exposed
to an inhibitory concentration of erythromycin. To assure 
adequate incorporation of label, the cells were grown in 
tryptone broth, which is a poorer medium than L broth but 
advantageously contains no uridine. As a result, the cells 
grow more slowly and a lower concentration of the drug is 
required for inhibition. Under these conditions 75 ug/ml of 
erythromycin was sufficient to limit cell growth by about 
80%. After cells reached their final densities they were 
collected and lysed. Ribosomal subunits were then separated 
on sucrose gradients and sedimentation profiles were 
constructed using the counts per minute of pH]-uridine and 
the absorbance at 260 nm per fraction (Figures 13A and B).
If degradation of ribosomes occured in the presence of the 
drug, the 50S subunit radioactivity peak would be expected to 
disappear or at least decline significantly. However, this 
did not occur. As Figure 13B shows, ribosomes prelabeled 
with pH]-uridine in the absence of the antibiotic were fairly 
stable during growth in the presence of the drug, showing a 
subunit radioactivity ratio reasonably close to that normally 
ejected (Table 6). However, the effect of erythromycin on 
assembly can be seen in the reduced amount of 50S subunits, 
reflected in the altered A^ ,, ratio of the subunits. This
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Figure 13. RIBOSOMAL SUBUNIT DEGRADATION ANALYSIS.
Ribosomal subunits fran strain SK901 were prelabeled by 
growth in I3H]-uridine. After dilution and uridine addition, 
the cells were grown in the presence or absence of 
erythromycin {75ug/ml). Subunits were then separated on 5-
20% sucrose gradients. The A260 (□) and cpm (•) profiles for 
subunits formed in the absence (A) and presence (B) of 
erythromycin were plotted.
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Table 6. Characteristics of Ribosomal Subunits from Cells 
Labeled in the Absence of Erythromycin.
5OS cum SOS A2£0 50S 3 OS S.A.
Sanqple 30S cpm 3OS Aaso cpm/Aaeo cpm/Aaso Ratio
SK901 (NE) 1.70 1.78 4,451 4,683 0.95
SK901 (E) 1.45 1.15 5,630 4,468 1.26
cpm/Aaeo = specific activity (S.A.); NE - no erythromycin; E = 
75 ug/ml erythrooiycin; S,A Ratio = SOS S.A./30S S.A.; All 
controls were repeatable within one standard deviation.
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result indicates that the antibiotic has a specific effect on 
the biosynthesis (and not the degradation) of the large 
ribosomal subunit in £. coli cells.
Ribosomal Assembly Analysis
This work was initiated to examine the hypothesis that 
macrolides might affect the formation of ribosomes in 
addition to their well established effects on translation. 
Ribosomal subunit assembly was monitored using a method 
previously described to study the assembly of ribosomes in 
several temperature-sensitive protein synthesis mutants 
(Champney, 1979).
The analysis was begun by labeling cells with [3HJ - 
uridine for several generations in the presence or absence of 
erythromycin (75 ug/ml). The radiolabeled subunits were 
separated from cell lysates by sucrose gradient 
centrifugation. Figure 14A shows a control gradient of 
ribosomal subunits from cells grown without erythromycin. As 
expected, a constant specific activity (cpm/A3G0) was found 
for each subunit and the 50S/30S specific activity ratio was 
1.0 (Table 7). in contrast, ribosomes formed during growth 
in the presence of erythromycin revealed a 50S subunit 
deficit (Figure 14B). The 50S/30S specific activity ratio 
for those ribosomes fell to 0.73. The fact that the specific 
activity ratio was less than 1 indicates that the effect was 
specific to the large subunit. Prolonged growth in the 
presence of erythromycin prior to labeling made this point 
even clearer. Gradients from cells labeled in this fashion
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Figure 14. RIBOSOMAL SUBUNIT ASSEMBLY ANALYSIS. Ribosomal 
subunits from strain SK901 were labeled with [3H] -uridine in
the absence (A) or presence of erythromycin (75 ug/ml) 
beginning one (B) or five hours (C) after the addition of 
drug. The A^q (P) and cpm (•) of each fraction was then 
plotted.
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Table 7. Characteristics of Riboscmal Subunit Assembly in 
the Presence of Erythromycin.
Sample
SOS cum 
3OS cpm
50S A26D 
30S Aaeo
50S
cpm/AsGo
30S
Cpm/Aaeo
S.A. 
Ratio
SK901 (NE) 1.84 1.81 43,362 42,706 1.02
SK901 (El) 0.98 1.35 27,307 37,475 0.73
SK901 (E2) 0.68 1.31 20,291 39,099 0.52
15201 (NE) 1.58 1.B2 452,759 523,126 0.87
N281 (75) 1.39 1.61 496,768 576,509 0.86
N281 (300) 0.79 1.13 199,377 284,505 0.70
N281 (450) 0.81 1.25 134,372 207,572 0.65
N282 (NE) 1.74 1.84 426,771 450,182 0.95
N282 (75) 1.86 1.94 486,404 508,504 0.96
N282 (300) 1.72 1.88 242,074 264,341 0.92
N282 (450) 1.29 1.47 205,022 233,468 0.88
cpm/Aaeo - specific activity (S.A.); NE = no erythromycin; El 
= 75 ug/ml erythromycin, 10 hr. label; E2 = 75 ug/ml 
erythronycin, 6 hr. label; (Number) = ug/ml erythromycin; All 
controls were repeatable within one standard deviation.
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showed that 50S biosynthesis was depressed even further over 
time (Figure 14C), showing a specific activity ratio of 0.52 
(Table 7).
Assembly Analysis of Mutant Ribosomes
Having established that erythromycin specifically 
inhibits 50S subunit assembly, ribosomes from the 
erythromycin resistant mutants N281 and N282 were examined 
for assembly defects in the same manner as those from the 
wild type strain SK901. Several different concentrations of 
erythromycin were used as it was expected that a higher 
concentration of erythromycin would be required to see an 
assembly effect, if one occurred.
Unlike wild type cells, neither mutant showed an 
assembly defect at a concentration of 75 ug/ml erythromycin 
(Figures 15B and 16B}. At a concentration of 300 ug/ml, a 
limited effect on assembly was observed in strain N281 
(Figure 15C), and at 450 ug/ml a reduction in 50S assembly 
was found similar to that observed in wild type cells at 75 
ug/ml (Figure 15D and Table 7). In contrast, no assembly 
defect was observed in strain N282 at 300 ug/ml erythromycin 
(Figure 16C). At the highest erythromycin concentration 
tested (450 ug/ml), only a limited effect on assembly was 
observed (Figure 16D and Table 7).
Assembly Effects of Related Drugs
It is well known that certain alterations in the central 
loop of domain V of the 23S rRNA secondary structure can
Figure 15. SUCROSE GRADIENT ANALYSIS OF STRAIN N281 
RIBOSOMES. Ribosomal subunits from strain N281 were prepared 
as before to examine assembly. The subunits were labeled in 
the absence (A) or presence of 75 (B); 300 (C); or 450 ug/ml 
erythromycin (D). The A ^  (□) and cpm (•) of each fraction 
was then plotted.
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Figure 16. SUCROSE GRADIENT ANALYSIS OF STRAIN N282 
RIBOSOMES. Ribosomal subunits from strain N282 were prepared 
as before for assembly analysis. The subunits were labeled 
in the absence (A) or presence of 75 (B); 300 (C); or 450 
ug/ml erythromycin (D). The A260 (□) and cpm (•) of each 
fraction was then plotted.
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produce so called MLS antibiotic resistance. To investigate 
the generality of the assembly effect of erythromycin, two 
other macrolides, a lincosamide, and a streptogramin were 
examined for their abilities to inhibit 50S assembly. 
Oleandomycin and spiramycin were chosen to represent the 14- 
and 16-membered macrolides, while lincamycin and 
virginianycin MA were selected to represent the remaining drug 
groups. Neither of the macrolides was found to effect 50S 
subunit assembly when tested at concentrations which reduced 
the rate of growth by 75% or more {Figures 17, 18 and Table 
8), Lincamycin (a lincosamide) appeared to have some effect 
on assembly although it did not seem to be identical to that 
of erythromycin (Figure 19A and Table 8). Virginiamycin HL (a 
streptogramin) on the other hand, did not have any noticeable 
effect on assembly (Figure 19B). These results seemed to 
indicate that erythromycin's effect on assembly was not 
generally applicable to all members of the MLS resistance 
group or, for that matter, to all macrolides (Table 8). 
However, to test this idea further, two recently developed 
derivatives of erythromycin A, azithromycin (9-deoxo-9a- 
methyl-9a-aza-9a-homo-erythranycin A) and clarithromycin (6- 
O-methylerythromycin) were examined as well. These two drugs 
have been modified to prevent the breakdown which occurs to 
erythromycin at low pH. Interestingly, azithromycin was 
found to be as effective as erythrcnycin in inhibiting 
assembly of the large subunit (Figure 20A). However, 
clarithronycin did not inhibit assembly (Figure 20B and Table
Figure 17. SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED 
DURING GROWTH IN OLEANDOMYCIN. RibOBOmal subunits from 
strain SK901 were prepared as before for erythromycin 
assembly experiments. The subunits were labeled with [3HJ- 
uridine in the presence of 80 (A) or 150 ug/ml (B) 
oleandomycin. The A260 {□} and cpm {•) of each fraction was 
then plotted.
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Figure 18. SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED 
DURING GROWTH IN SPIRAMYCIN. Ribosomal subunits from strain 
SK901 were prepared as before for erythromycin assembly 
experiments. The subunits were labeled with [3H]-uridine in 
the presence of 80 (A) or 150 ug/ml (B) spiramycin. The A260 
(□} and cpm (•) of each fraction was then plotted.
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Figure 19. SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED 
DURING GROWTH IN LINCOMYCIN AND VIRGINIAMYCIN M^ Ribosomal 
subunits from strain SK901 were prepared as before for 
erythromycin assembly experiments. The subunits were labeled 
with pH] -uridine in the presence of 75 ug/ml lincamycin (A)
or 20 ug/ml Virginiamycin Mi {B). The A260 (0) CP™ (•) of 
each fraction was then plotted.
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Table 8. Characteristics of Ribosomal Subunit Assembly in 
the Presence of Other Drugs.
Sample
5JQS_CBH 
3os cpm
50S Aaco 
30S Aaeo
50S
cpm/Aaco
3 OS 
cpm/Aaeo
S.A. 
Ratio
SK901(080) 1.86 1.91 318,603 327,467 0.97
SK901(0150) 1.78 1.84 328,811 340,717 0.97
SK901(S80) 1.74 1.85 274,197 291,035 0.94
SK901 (S150) 1.89 1.74 295,503 272,382 1.08
SK901(L75) 1.30 1.30 205,353 205,111 1.00
SK90KV20) 1.77 1.89 82,435 88,433 0.93
SK901(A2.5) 0.94 1.36 113,796 163,734 0.70
SK901(C20) 1.68 1.70 103,389 103,906 1.00
cpm/Aaco « specific activity; (Letter Number) *= Drug, pg/ml
Drug; o = oleandomycin; S = spiramycin; V = virginiamycin Mlf- 
L » lincamycin; A = azithromycin; C = clarithromycin; All 
controls were repeatable within one standard deviation.
Figure 20. SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED 
DURING GROWTH IN AZITHROMYCIN AND CLARITHROMYCIN. Ribosomal 
subunits from strain SK901 were prepared as before for 
assembly experiments. The subunits were labeled with [3H] - 
uridine in the presence of 2.5 ug/ml azithromycin (A) or 20 
ug/ml clarithromycin (B). The A2S0 {□} and cprn (•} of each 
fraction was then plotted.
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Chapter 4 
Discussion
This work began as an attempt to better define the 
interaction(s) between erythromycin and the £. coll ribosome 
by identifying ribosomal protein sequences important for 
resistance. As is often the case in studies of this nature, 
mutants exhibiting an altered phenotype for the
i
characteristic under examination can frequently be useful in 
probing any interactions which may exist. The strains (N281 
and N2B2) used in these experiments were originally isolated 
as spontaneous mutants resistant to high concentrations of 
erythromycin (Apirion, 1967) and, therefore provided a useful 
tool for the examination of this ribosome-drug interaction.
Previous analysis of ribosomal proteins from mutant N281 
revealed that protein L22 possessed an altered 
electrophoretic mobility at pH 8.6 (Wittmann et al., 1973). 
However, the protein responsible for resistance in mutant 
N282 could not be detected using this method. Analysis of 
the L4 protein from this mutant on a carboxymethyl cellulose 
column indicated that the protein had an altered elution 
profile at pH 5.6. Based on the Buccess of this low pH 
separation, an alternate two-dimensional electrophoresis 
technique (at similar pH) was employed in this work. As 
expected, both mutant proteins showed an altered first- 
dimension mobility in the second gel system.
In order to more precisely define the nature of the 
alterations in these mutants, the appropriate ribosomal
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protein genes were sequenced from each resistant mutant. The 
wild type sequences found for the rplV and rplD genes agreed 
exactly with those reported by ZurawBki and Zurawski (1985) 
with one exception. The rplD sequence contained a CAG codon 
for Gin at position 30 in place of the reported CAA codon 
which also codes for that amino acid (Zurawski and Zurawski 
1965). unlike the the point mutation found in the rplD gene 
of the L4 mutant, the deletion of nine nucleotides from the 
rplV gene of the L22 mutant was somewhat unexpected. Close 
examinination of the deleted region for possible secondary 
structures using the DMA analysis program *DNASISW revealed 
that a reasonably stable stem-loop structure (-1.2 kcal/mole) 
was possible (Figure 21). significantly, the deleted region 
of the rplV gene was entirely contained in the loop. It 
seems likely that this area might be susceptible to 
deoxyribonuclease activity and therefore to deletion.
The altered electrophoretic mobilities detected for 
these proteins would predict a more negative form of each 
protein. Both the lysine to glutamate alteration in 1A 
(N282) and the Met-Lys-Arg deletion found in L22 (N281) are 
entirely consistent with this prediction. One apparent 
inconsistency is the fact that wittmann et al. (1973) were 
unable to detect an elctrophoretic mobility change for the L4 
protein of mutant N282 at pH 8.6. This is most likely 
explained by the lack of reference points near that protein 
in the pH 6.6 electrophoretic system. A small change such as 
the one likely to occur would be difficult to detect. The 
identification of these sequence alterations is quite
Figure 21. PROPOSED SECONDARY STRUCTURE FOR THE r p l V  GENE 
DELETION REGION. Possible stem-loop structure for the 
deleted region of the L22 gene. Arrows indicate the 
boundaries of the deletion. The four base repeats flanking 
the deletion are enclosed in boxes.
A = T
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significant. Their identification represents the first 
sequence changes to he reported for ribosomal proteins from 
an erythromycin-resistant mutant. These studies also 
identify critical components of the sequences of two 
different ribosomal proteins necessary for the interaction of 
erythromycin with the bacterial ribosome. These observations 
should help in identifying the important amino acid and 
nucleotide residues involved in the binding and inhibitory 
effects of the compound.
A comparison of the altered protein sequences from the 
mutants used in these experiments with the homologous 
ribosomal proteins of several other organisms revealed that 
both regions are highly conserved (Tables 9 and 10). The 
sequence surrounding the L4 mutation site shows canplete 
identity in 2£. nseudotuberculosis and strong homology with 
the Mycoplasma homolog (Table 9). The altered region of 
protein h22 also demonstrated strong homology with sequences 
from two other prokaryotic L22 hamologs (Bacillus and 
Mycoplasmal (Table 10). In the four chloroplast genes 
examined additional significant homology was observed with 
the region surrounding the L22 deletion site. The fact that 
ribosomes from these cells and plastids are sensitive to 
erythromycin (Mets and Bogorad, 1971; Qcmira, 1984) is 
compelling evidence for the importance of these regions in 
the erythromycin-ribosome interaction. This point is 
strengthened by the fact that L22-like sequences from 
archaebacteria and rat (Arndt et al., 1990; Laine et al.,
1991) which show little sensitivity to these drugs (Amils et
Table 9. Ribosomal Protein L4 Homologies
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Organism Sequence ft Homology Reference
Escherichia
coll
Yersinia
psuedotuber.
Mycoplasma
capricolum
PWRQgGTGR 100 (201) (Zurawski and 
Zurawski 1985)
FWRQXGTGR 94.5 (210) (Gross et al., 1989)
PWKQKGTGL 35.8 (193) (Ohkubo et al, 1987}
Residues altered in erythromycin-resistant ribosomal proteins 
are double underlined. Identical amino acids from L4 
homologs in other organisms are in bold. The percent of 
overall sequence homology is given along with the total 
number of amino acids in each homolog which is indicated in 
parentheses.
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Table 10. Ribosomal Protein L22 Homologies.
Organism
Escherichia
£Qli
Mycoplasma
caprlcolum
Bacillus
stearotherm.
Liverwort
(chloroplast)
Red algae 
(chloroplast)
Spinach
(chloroplast)
Tobacco
(chloroplast)
Rat liver
Halobacteriuro
marismortui
Sequence ft.-HOmology Reference
QPSMKRIMP
GPTLKRFRP
GPTLKRFRP
gtffkrfqp
GPKLKRFQP
OITLKKVKP
GTTVKKLKP
APKMRRRSG
VGESQGRKP
100 (110) (Zurawski and
Zurawski, 1985)
54.1 (109) (Ohkubo et al., 1987)
52.8 (108) (Kroner et al., 1990)
41.6 (101) (Fukuzawa et al.,
1988)
40.6 (101) (Kao and Hu, 1990)
38.1 (97) (Zhou et al., 1989)
37.6 (101) (Tanaka et al., 1986)
32 (109) (Laine et al., 1991)
17.8 (90) (Arndt et al., 1990)
Residues altered in erythromycin-resistant ribosomal proteins 
are double underlined. Identical amino acids from L22 
homologs in other organisms are in bold. The percent of 
overall sequence homology is given along with the total 
number of amino acids in each homolog which is indicated in 
parentheses.
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al., 1990) also have poor homology. These results suggest 
that ribosomes from other prokaryotes, or from mitochondria 
that have significant sequence homology to £. coli ribosomal 
proteins L4 and L22 should be sensitive to inhibition by 
erythromycin, as was demonstrated previously (Lamb et al., 
1968).
A number of recent studies have identified several 23S 
ribosomal RNA mutations in £. cflli (Douthwaite, 1992;
Ettayebi et al., 1985; Sigmund and Morgan, 1982) and other 
organisms { Vester and Garrett, 1987 and references therein) 
which also lead to the erythromycin resistance phenotype. 
These sequence changes are almost exclusively located in 
domain V of the RNA secondary structure with the exception of 
one deletion affecting domain II described b y Douthwaite et 
al. (1985). This is a significant finding when one considers 
that proteins 14 and L22 interact with each other in binding 
to 23S rRNA at sequences associated with domain II (Herold 
and Nierhaus, 1987).
These experiments have also provided evidence that 
erythromycin has a second mechanism of action. Perhaps the 
first clue to this was the observation that the expression of 
wild type and mutant alleles in merodiploid cells was 
different in the presence and absence of the drug. Two- 
dimensional electrophoresis of ribosomal proteinB from 
particles formed under each condition demonstrated this 
clearly. Those experiments showed that a considerable excesB 
of wild type protein was present in ribosomal particles from 
cells grown under permissive conditions (no erythromycin
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present) while mutant protein predominated in the presence of 
the drug. This difference in protein content waB alBO 
reflected in the relative sensitivity of the two complemented 
mutants to increasing concentrations of erythromycin. The 
L22 diploid was far more sensitive to higher concentrations 
of the macrolide than it's L4 counterpart was under the same 
conditions. A quantitative comparison of the relative 
expression of these genes revealed that plasmid copy number 
differences were not a factor in the distribution of protein 
forms.
However, it is conceivable that transcription might be 
effected in the presence of the L4 plasmid (pLF 4.6) since 
expression of the S10 operon is under autogenous control of 
protein L4. Termination of trancription for the operon is 
specically elevated with increasing concentrations of free L4 
(Zengel and Lindahl, 1990). under those conditions one would 
expect to see a decrease in the ratio of mutant versus wild 
type protein conpared to that of the L22 proteins, since pLF
4.6 transcription would be independent of that regulation. 
However, this was not the case, possibly this is due to the 
alteration present in the mutant form of L4. It is possible 
that the mutant protein is not capable of the same regulatory 
function or at least is not as efficient. Such questions can 
only be answered by quantifing mRNA levels from both the 
plasmid and the chromosomal genes, since the two are under 
the control of different promoters.
Further evidence for a second mechanism was provided by 
the fact that differences in binding affinities for the drug
have been observed for each of these mutants. Previous 
examination of ribosomes from the 1A mutant showed that they 
bound erythromycin poorly and had a reduced 
peptidyltransferase activity. Curiously, neither of these 
features were found for ribosomes isolated from the L22 
mutant {wittmann et al., 1973). These results agree with the 
binding data reported here, although somewhat less binding 
was found in these experiments compared with that reported by 
Wittmann et al. (1973). This is most likely a result of the 
inactivation of a greater percentage of ribosomes during the 
purification process. Given these results, the basis for 
resistance in the L22 strain seemed less clear. However, the 
possibility of a second mode of action for the drug seemed 
more likely.
The assembly experiments presented here provide strong 
evidence that erythromycin has two independent but related 
effects on protein biosynthesis in Escherichia coli cells.
The functional effect of this antibiotic is to prevent the 
elongation of short polypeptide chains during translation, 
interfering with a step after initiation (Andersson and 
Kurland, 1987; Vester and Garrett, 1987). This work also 
shows that an additional structural effect of the compound is 
to block ribosomal subunit formation, probably early in the 
assembly process. SOS subunit formation is specifically 
affected, since breakdown is not stimulated and the 30S 
subunit is unaffected. These results differ from the 
conclusion of Vester and Garrett (1987) that erythromycin 
apparently stimulated the degradation of 5OS subunits in a
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merodiploid strain containing 23S rRNA alleles for 
sensitivity and resistance to erythromycin. However, 
differences in strains and experimental conditions makes a 
direct comparison with these results difficult. It is 
important to note the the efficacy of erythromycin and 
azithromycin in vivo is much greater than that of 
oleandomycin, clarithromycin or spiramycin, consistent with 
the two site effect of the former compounds (Nakayama, 1984; 
Whitman and Tunkel, 1992) .
Although the MLS resistance drug group does not appear 
to effect assembly as a whole, it is still not clear from 
this work whether other members of this drug group might have 
an effect, it is clear however, that the macrolide effect on 
assembly is restricted to erythromycin and azithromycin among 
the antibiotics examined here. A number of studies have 
indicated that erythronycin interacts with both sequences in 
the 23S ribosomal RNA and with ribosomal proteins L4 and L22 
(Arevalo et al., 1988; Coopeman et al., 1990; Douthwaite et 
al., 1985; Ettayebi et al., 1985; Moazed and Noller, 1987; 
Sigmund and Morgan, 1982; Teraoka and Nierhaus, 1978). Since 
the assembly defect is significantly reduced in resistant 
mutantB with an altered L22 or L4 protein, it seems clear 
that these proteins are part of the binding site for the drug 
on the 50S subunit.
These results suggest a model for the effect of 
erythronycin on assenibly, based on two facts. A comparison 
of the structures of erythromycin and azithrontycin (which 
prevent assembly) and of oleandomycin and clarithromycin
(which do not), reveals that the former compounds contain a 
pair of cis hydroxyl groups at positions 6 and 12 of the 
macrolactone ring (Figure 22). Oleandomycin lacks both of 
these hydroxyl groups and clarithromycin is a 6-0- 
methylerythranycin (Nakagawa and Ontura, 1984; Whitman and 
Tunkel, 1992). This inplies that the 6-OH group is important 
in promoting the assembly deficiency. In addition, the 
mutational change in protein L4 conferring assembly 
resistance involves the loss of a baBic amino acid residue.
I propose that erythromycin (and azithromycin) interferes 
with the binding of L4 to 23S rRNA early in the assembly 
process and that an electrostatic interaction between the 6- 
OH group of the drug and Lys 63 of L4 is critical for this 
effect. Loss of the positive charge (as in the mutant 
strain) or the absence of the 6-hydroxyl group (as in 
oleandonycin and clarithromycin) would allow assembly to 
proceed. Protein L4 is a strong 23S rRNA binding protein 
associating with the 5f end of the RNA (Nierhaus, 1982). It 
is also noteworthy that the erythronycin-resistant mutant 
N282 is cold-sensitive for growth at 20°C, and is 50S subunit 
assenbly defective under those conditions (Champney, 
unpublished observations). This subunit assembly defect has 
been observed for several other cold-sensitive mutants 
(Bryant and Sypherd, 1974; Guthrie et al., 1969) including a 
strain with an L22 protein mutation (Pardo et al.r 1979). 
Apparently the price for resistance to erythronycin in the L4 
mutant is ribosomal instability at low tenperature.
These findings suggest two important directions to be
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Figure 22. MACROLIDE drug structures. Molecular structures 
of erythromycin a , oleandomycin, azithromycin, and 
clarithromycin. Hydroxyl groups at positions 6 and 12 (as 
they relate to erythromycin A's structure) are indicated in 
bold.
HO -------
ERYTHROMYCIN A OLEANDOMYCIN
AZITHROMYCIN CLARITHROMYCIN
pursued. The in vitro reconstitution of the large subunit 
should be performed in the presence of erythromycin to help 
define the site and stage in assetribly at which the inhibition 
occurs. It will also be important to test other 
microorganisms (especially Gram positive cells) to explore 
the generality of this novel effect of the macrolide 
antibiotic drug group on ribosome formation.
Finally, these results indicate a second parameter to be 
evaluated when new macrolide antibiotics are under review for 
effectiveness. This pronounced effect on riboscmal assembly 
indicates that this may be an equally important target for 
drug activity as is an inhibition of translation. It is also 
important to be reminded that the idea of "one drug one 
action" is not necessarily true.
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